Thomas Kaufmann has 13 years of experience in the financial industry. Before joining Kieger AG, he worked for a Swiss biotech company active in the field of oncology. Prior to that, he spent more than 10 years as pharmaceutical/biotech analyst for Credit Suisse’s private banking and then investment banking divisions. He was also responsible for the “innovation” megatrend.
Thomas Kaufmann studied biochemistry and obtained his PhD in biophysics (structural biology) at the Biozentrum of the University of Basel.